CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) - USD ($) shares in Millions, $ in Millions		3 Months Ended
		Apr. 02, 2023	Apr. 03, 2022
Income Statement [Abstract]
Revenues		$ 18,282	$ 25,661
Costs and expenses:
Cost of sales	[1]	4,886	9,984
Selling, informational and administrative expenses	[1]	3,418	2,593
Research and development expenses	[1]	2,505	2,301
Acquired in-process research and development expenses		21	355
Amortization of intangible assets		1,103	835
Restructuring charges and certain acquisition-related costs		9	192
Other (income)/deductions––net		70	350
Income from continuing operations before provision/(benefit) for taxes on income	[2]	6,270	9,050
Provision/(benefit) for taxes on income		715	1,172
Income from continuing operations		5,555	7,879
Discontinued operations––net of tax		1	(9)
Net income before allocation to noncontrolling interests		5,556	7,870
Less: Net income attributable to noncontrolling interests		13	6
Net income attributable to Pfizer Inc. common shareholders		$ 5,543	$ 7,864
Earnings per common share––basic:
Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)		$ 0.98	$ 1.40
Discontinued operations––net of tax (in dollars per share)		0	0
Net income attributable to Pfizer Inc. common shareholders (in dollars per share)		0.98	1.40
Earnings per common share––diluted:
Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)		0.97	1.37
Discontinued operations––net of tax (in dollars per share)		0	0
Net income attributable to Pfizer Inc. common shareholders (in dollars per share)		$ 0.97	$ 1.37
Weighted-average shares––basic		5,634	5,617
Weighted-average shares––diluted		5,727	5,758

[1] Exclusive of amortization of intangible assets.

[2] Income from continuing operations before provision/(benefit) for taxes on income. Biopharma’s earnings include dividend income from our investment in ViiV of $92 million in the first quarter of 2023 and $56 million in the first quarter of 2022. In connection with the organizational changes effective in the third quarter of 2022, certain functions transferred between Biopharma and corporate enabling functions and certain activities were realigned within the GPD organization. We have reclassified $47 million of costs in the first quarter of 2022 from corporate enabling functions, which are included in Other business activities, to Biopharma to conform to the current period presentation.